The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta …
Aims To estimate the association of smoking status with rates of (i) infection,(ii)
hospitalization,(iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease …
hospitalization,(iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease …
Infectious Diseases Society of America guidelines on the diagnosis of coronavirus disease 2019
IDSA Disclaimer As of the time of this publication, updates have been made to IDSA's
Guidelines on the Diagnosis of COVID-19. For the most updated version of these guidelines …
Guidelines on the Diagnosis of COVID-19. For the most updated version of these guidelines …
Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis
MP Sormani, N De Rossi, I Schiavetti… - Annals of …, 2021 - Wiley Online Library
Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …
Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis
A Salter, RJ Fox, SD Newsome, J Halper… - JAMA …, 2021 - jamanetwork.com
Importance Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather
information on clinical outcomes and risk factors associated with morbidity and mortality in …
information on clinical outcomes and risk factors associated with morbidity and mortality in …
COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies
AT Reder, D Centonze, ML Naylor, A Nagpal… - CNS drugs, 2021 - Springer
Abstract Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target
immunity and have the potential to increase the risk of severe acute respiratory syndrome …
immunity and have the potential to increase the risk of severe acute respiratory syndrome …
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
A Zabalza, S Cárdenas‐Robledo… - European journal of …, 2021 - Wiley Online Library
Background and purpose Information regarding multiple sclerosis (MS) patients with the
2019 novel coronavirus disease (COVID‐19) is scarce. The study objective was to describe …
2019 novel coronavirus disease (COVID‐19) is scarce. The study objective was to describe …
Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review
Background: Numerous cases of the coronavirus disease 2019 (COVID-19) with
autoimmune and rheumatic manifestations have been reported. Despite the available …
autoimmune and rheumatic manifestations have been reported. Despite the available …
COVID-19 among patients with multiple sclerosis: a systematic review
M Barzegar, O Mirmosayyeb… - Neurology …, 2021 - AAN Enterprises
Objective We systematically reviewed the literature on COVID-19 in patients with multiple
sclerosis (MS). Methods We searched PubMed, Scopus, EMBASE, CINAHL, Web of …
sclerosis (MS). Methods We searched PubMed, Scopus, EMBASE, CINAHL, Web of …
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis
MA Sahraian, A Azimi, S Navardi, S Ala… - Multiple sclerosis and …, 2020 - Elsevier
Background COVID-19 is increasingly expanding all over the world. People who have an
underlying disease or taking immunosuppressive drugs are generally more likely to be …
underlying disease or taking immunosuppressive drugs are generally more likely to be …
Emerging COVID-19 neurological manifestations: present outlook and potential neurological challenges in COVID-19 pandemic
S Dewanjee, J Vallamkondu, RS Kalra… - Molecular …, 2021 - Springer
The unremitting coronavirus disease 2019 (COVID-19) pandemic caused by the novel
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) marked a year-long phase …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) marked a year-long phase …